GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clovis Oncology Inc (OTCPK:CLVSQ) » Definitions » Beneish M-Score

Clovis Oncology (Clovis Oncology) Beneish M-Score : 0.00 (As of Apr. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Clovis Oncology Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Clovis Oncology's Beneish M-Score or its related term are showing as below:

During the past 12 years, the highest Beneish M-Score of Clovis Oncology was 0.00. The lowest was 0.00. And the median was 0.00.


Clovis Oncology Beneish M-Score Historical Data

The historical data trend for Clovis Oncology's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clovis Oncology Beneish M-Score Chart

Clovis Oncology Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 630.90 -1.17 -2.02 -3.11 -2.93

Clovis Oncology Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.92 -2.93 -2.75 -3.54 -3.72

Competitive Comparison of Clovis Oncology's Beneish M-Score

For the Biotechnology subindustry, Clovis Oncology's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clovis Oncology's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clovis Oncology's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Clovis Oncology's Beneish M-Score falls into.



Clovis Oncology Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Clovis Oncology for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8491+0.528 * 1.0307+0.404 * 1.3062+0.892 * 0.8522+0.115 * 0.9068
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0845+4.679 * -0.195672-0.327 * 1.5285
=-3.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep22) TTM:Last Year (Sep21) TTM:
Total Receivables was $22.6 Mil.
Revenue was 30.663 + 32.143 + 34.247 + 35.968 = $133.0 Mil.
Gross Profit was 22.055 + 22.928 + 24.834 + 26.238 = $96.1 Mil.
Total Current Assets was $102.2 Mil.
Total Assets was $346.8 Mil.
Property, Plant and Equipment(Net PPE) was $21.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $7.7 Mil.
Selling, General, & Admin. Expense(SGA) was $125.5 Mil.
Total Current Liabilities was $747.9 Mil.
Long-Term Debt & Capital Lease Obligation was $16.8 Mil.
Net Income was -56.014 + -71.332 + -60.169 + -64.391 = $-251.9 Mil.
Non Operating Income was -1.881 + -2.318 + -0.83 + -3.448 = $-8.5 Mil.
Cash Flow from Operations was -40.61 + -35.127 + -58.495 + -41.343 = $-175.6 Mil.
Total Receivables was $31.3 Mil.
Revenue was 37.916 + 36.82 + 38.053 + 43.299 = $156.1 Mil.
Gross Profit was 28.067 + 27.183 + 28.442 + 32.482 = $116.2 Mil.
Total Current Assets was $230.7 Mil.
Total Assets was $508.0 Mil.
Property, Plant and Equipment(Net PPE) was $27.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.5 Mil.
Selling, General, & Admin. Expense(SGA) was $135.8 Mil.
Total Current Liabilities was $112.7 Mil.
Long-Term Debt & Capital Lease Obligation was $620.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(22.619 / 133.021) / (31.257 / 156.088)
=0.170041 / 0.200252
=0.8491

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(116.174 / 156.088) / (96.055 / 133.021)
=0.744285 / 0.722104
=1.0307

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (102.209 + 21.515) / 346.775) / (1 - (230.666 + 27.181) / 507.997)
=0.643215 / 0.492424
=1.3062

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=133.021 / 156.088
=0.8522

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(8.549 / (8.549 + 27.181)) / (7.712 / (7.712 + 21.515))
=0.239267 / 0.263866
=0.9068

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(125.528 / 133.021) / (135.813 / 156.088)
=0.943671 / 0.870105
=1.0845

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((16.791 + 747.87) / 346.775) / ((620.14 + 112.693) / 507.997)
=2.205064 / 1.442593
=1.5285

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-251.906 - -8.477 - -175.575) / 346.775
=-0.195672

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Clovis Oncology has a M-score of -3.72 suggests that the company is unlikely to be a manipulator.


Clovis Oncology Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Clovis Oncology's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Clovis Oncology (Clovis Oncology) Business Description

Traded in Other Exchanges
N/A
Address
5500 Flatiron Parkway, Suite 100, Boulder, CO, USA, 80301
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.
Executives
Thomas C. Harding officer: See Remarks 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Gillian C Ivers-read officer: See Remarks C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Lindsey Rolfe officer: See remarks C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Daniel W Muehl officer: See remarks 5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862
Paul Edward Gross officer: See Remarks 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302
Ronit Simantov director 1988 CHAPEL STREET, NEW HAVEN CT 06515
James C Blair director 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Patrick J Mahaffy director, officer: President and CEO C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Thorlef Spickschen director TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000
Richard A. Fair director C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Hooks Corwin Dale officer: See remarks C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301
Paul H Klingenstein director 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
Ginger L Graham director AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

Clovis Oncology (Clovis Oncology) Headlines

From GuruFocus